Caius Radu
Founder
Trethera
Trethera develops small molecules that inhibit the enzyme dCK, targeting nucleotide metabolism to disrupt DNA replication in cancer cells and modulate immune responses in autoimmune diseases. Their lead candidate, TRE-515, is designed to treat specific solid tumors with metabolic vulnerabilities and enhance the efficacy of existing therapies.
- Biotechnology
Updated 7 months ago
Funding
Raised to date
$250KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Cancer cells exhibit distinct metabolic processes compared to healthy cells, particularly in DNA replication and repair. This difference creates vulnerabilities that can be exploited for targeted cancer therapies. Additionally, the enzyme dCK, involved in nucleotide metabolism, may play a role in immune activation, potentially contributing to autoimmune diseases.
Solution
Trethera is developing small molecule inhibitors of the enzyme deoxycytidine kinase (dCK) to disrupt nucleotide metabolism in cancer cells and modulate immune responses in autoimmune diseases. Their lead candidate, TRE-515, targets the salvage pathway of nucleotide biosynthesis, a critical process for DNA replication and repair. By inhibiting dCK, TRE-515 aims to selectively disrupt DNA replication in cancer cells with underlying metabolic sensitivities. This approach is designed to be effective as a monotherapy in specific solid tumors or in combination with other therapeutics to enhance efficacy and overcome resistance.
Target Audience
The primary target audience includes patients with specific solid tumors exhibiting metabolic vulnerabilities and individuals suffering from autoimmune diseases where modulation of immune responses is desired.
Features
- TRE-515: A small molecule inhibitor targeting the enzyme dCK.
- Designed to disrupt DNA replication in cancer cells by inhibiting nucleotide metabolism.
- Potential to modulate immune responses in autoimmune diseases.
- Selective targeting of cancer cells with metabolic vulnerabilities.
- Potential for combination therapy to enhance efficacy or overcome resistance.